Although many manuscripts have published that all receptors have been associated with inducing and inhibiting tumor and immune cell migration depending on the cell stimulated, the use of receptor antagonists to EP2 and EP4 have been shown to inhibit breast cancer progression [42]. Here, PTGER4 is linked to neoplasm.